Payment overview · 2025
General Payments
$682.68
27 reported records · 13 companies
Healthcare provider profile · identity verified
Albert Russell Vaughn, MD
Allopathic & Osteopathic Physicians|Pediatrics · JEFFERSON CITY, TN · NPI 1689084865
Verified facts
What the public records show
CMS Open Payments records show Albert Russell Vaughn, MD received $682.68 in general payments during 2025 across 27 reported records.
HEARTFLOW, INC. accounted for 35.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Eliquis, Jardiance, Ozempic, Shingrix, Trelegy Ellipta.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $240.50 | 35.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $133.76 | 19.6% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.32 | 10.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.53 | 7.5% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.49 | 4.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$27.34 | 4.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.14 | 3.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.96 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.91 | 2.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.56 | 2.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.97 | 2.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.35 | 2.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $13.85 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $682.68 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $240.50 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $111.68 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.33 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.33 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $29.49 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $27.34 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 57 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 49 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 111 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 96 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
111 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
49 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
96 | 75 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
57 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
111 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 427 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 235 | 80 |
| Omeprazole | Omeprazole | 203 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 50 |
| Lisinopril | Lisinopril | 166 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 64 |
| Gabapentin | Gabapentin | 147 | 59 |
| Meloxicam | Meloxicam | 140 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 48 |
| Celecoxib | Celecoxib | 127 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 47 |
| Trazodone Hcl | Trazodone Hcl | 123 | 43 |
| Losartan Potassium | Losartan Potassium | 122 | 45 |
| Montelukast Sodium | Montelukast Sodium | 120 | 38 |
| Simvastatin | Simvastatin | 113 | 35 |
| Eliquis | Apixaban | 111 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 30 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 96 | 75 |
| Alprazolam | Alprazolam | 95 | 20 |
| Metformin Hcl Er | Metformin Hcl | 91 | 35 |
| Buspirone Hcl | Buspirone Hcl | 89 | 22 |
| Sertraline Hcl | Sertraline Hcl | 84 | 23 |
| Finasteride | Finasteride | 81 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 24 |
| Ozempic | Semaglutide | 73 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 20 |
| Lorazepam | Lorazepam | 72 | 21 |
| Tramadol Hcl | Tramadol Hcl | 72 | 22 |
| Alendronate Sodium | Alendronate Sodium | 71 | 19 |
| Furosemide | Furosemide | 68 | 27 |
| Potassium Chloride | Potassium Chloride | 68 | 21 |
| Prednisone | Prednisone | 68 | 31 |
| Clonazepam | Clonazepam | 65 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 22 |
| Ezetimibe | Ezetimibe | 62 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 15 |
| Famotidine | Famotidine | 58 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 57 | 57 |
| Allopurinol | Allopurinol | 56 | 17 |
| Metformin Hcl | Metformin Hcl | 56 | 20 |
| Carvedilol | Carvedilol | 54 | 19 |
| Glimepiride | Glimepiride | 54 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 20 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 49 | 49 |
| Methocarbamol | Methocarbamol | 49 | 13 |
| Atenolol | Atenolol | 48 | 16 |
| Benazepril Hcl | Benazepril Hcl | 44 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 12 |
| Estradiol | Estradiol | 40 | 14 |
| Jardiance | Empagliflozin | 39 | 13 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 11 |
| Temazepam | Temazepam | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 13 |
| Diazepam | Diazepam | 33 | suppressed |
| Nystatin | Nystatin | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 19 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 17 |
| Mupirocin | Mupirocin | 29 | 21 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | 12 |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 14 |
| Baclofen | Baclofen | 25 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 25 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 15 |
| Sucralfate | Sucralfate | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | 17 |
| Topiramate | Topiramate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $682.68 · 27 records | HEARTFLOW, INC. | ABRYSVO, AREXVY, BodyGuardian, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, ETERNA, FFRct, GVOKE HYPOPEN, JARDIANCE, MINIMED 780G, NURTEC ODT, Nubeqa, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, Wegovy, Xofigo, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error